bluuebunny/crossref_metadata_2025_split huggingface dataset:
Know Your Enemy
Authors: Basin David , Cremers Cas 
Published: November 2014

We present a symbolic framework, based on a modular operational semantics, for formalizing different notions of compromise relevant for the design and analysis of cryptographic protocols. The framework’s rules can be combined to specify different adversary capabilities, capturing different practically-relevant notions of key and state compromise. The resulting adversary models generalize the models currently used in different domains, such as security models for authenticated key exchange. We extend an existing security-protocol analysis tool, Scyther, with our adversary models. This extension systematically supports notions such as weak perfect forward secrecy, key compromise impersonation, and adversaries capable of state-reveal queries. Furthermore, we introduce the concept of a protocol-security hierarchy, which classifies the relative strength of protocols against different adversaries.
In case studies, we use Scyther to analyse protocols and automatically construct protocol-security hierarchies in the context of our adversary models. Our analysis confirms known results and uncovers new attacks. Additionally, our hierarchies refine and correct relationships between protocols previously reported in the cryptographic literature.
The deepwater demersal ichthyofauna of the western Coral Sea
Authors: LAST PETER R. , POGONOSKI JOHN J. , GLEDHILL DANIEL C. , WHITE WILLIAM T. , WALKER CHRIS J. 
Published: November 2014

The highly diverse deepwater demersal ichthyofauna of the western Coral Sea was first systematically surveyed in two exploratory voyages in 1985 and 1986, and these fish assemblages have not been investigated at the same level since. Only recently have catch data and specimens, obtained from these first voyages almost 3 decades ago, been rigorously investigated and analysed. Some 393 species of fishes from 125 families were collected during the 1985 voyage which surveyed the northeastern Australian continental margin, and the Saumarez and Queensland Plateaus. A checklist of the species caught is provided. Levels of endemicity of deepwater fishes in the western Coral Sea are very high with about 50% of well-studied groups, such as sharks and rays, confined to this relatively small geographic region. A very high proportion of species caught during this voyage were either undescribed (78 species or 20%) or new Australian records (96 species or 24%) at the time of the survey. Another 68 species (17%) are the subject of further taxonomic investigation or are currently undergoing formal description. The fauna exhibits some intraregional differences in structure. Biogeographically informative fishes such as skates appear to be cryptically partitioned within the region, differing in composition to other Australian regions and those of French territories to the east. Strong depth-related partitioning of the fauna is also evident, and its structure follows zonation patterns observed across the wider Australian region. Given the high level of micro-endemicity and regional uniqueness of the fauna, there is a compelling argument for the existence of a faunal gyre in the Coral Sea. New gap-filling surveys are needed to better define the structure of this fauna and determine its distribution.
Statistical Postprocessing of High-Resolution Regional Climate Model Output
Authors: Mendoza Pablo A. , Rajagopalan Balaji , Clark Martyn P. , Ikeda Kyoko , Rasmussen Roy M. 
Published: November 2014

Abstract
Statistical postprocessing techniques have become essential tools for downscaling large-scale information to the point scale, and also for providing a better probabilistic characterization of hydrometeorological variables in simulation and forecasting applications at both short and long time scales. In this paper, the authors assess the utility of statistical postprocessing methods for generating probabilistic estimates of daily precipitation totals, using deterministic high-resolution outputs obtained with the Weather Research and Forecasting (WRF) Model. After a preliminary assessment of WRF simulations over a historical period, the performance of three postprocessing techniques is compared: multinomial logistic regression (MnLR), quantile regression (QR), and Bayesian model averaging (BMA)—all of which use WRF outputs as potential predictors. Results demonstrate that the WRF Model has skill in reproducing observed precipitation events, especially during fall/winter. Furthermore, it is shown that the spatial distribution of skill obtained from statistical postprocessing is closely linked with the quality of WRF precipitation outputs. A detailed comparison of statistical precipitation postprocessing approaches reveals that, although the poorest performance was obtained using MnLR, there is not an overall best technique. While QR should be preferred if skill (i.e., small probability forecast errors) and reliability (i.e., match between forecast probabilities and observed frequencies) are target properties, BMA is recommended in cases when discrimination (i.e., prediction of occurrence versus nonoccurrence) and statistical consistency (i.e., equiprobability of the observations within their ensemble distributions) are desired. Based on the results obtained here, the authors believe that future research should explore frameworks reconciling hierarchical Bayesian models with the use of the extreme value theory for high precipitation events.
Agricultural Advisors as Climate Information Intermediaries: Exploring Differences in Capacity to Communicate Climate
Authors: Haigh Tonya , Morton Lois Wright , Lemos Maria Carmen , Knutson Cody , Prokopy Linda Stalker , Lo Yun Jia , Angel Jim 
Published: November 2014

Abstract
Although agricultural production faces chronic stress associated with extreme precipitation events, high temperatures, drought, and shifts in climate conditions, adoption of climate information into agricultural decision making has been relatively limited. Agricultural advisors have been shown to play important roles as information intermediaries between scientists and farmers, brokering, translating, and adding value to agronomic and economic information of use in agricultural management decision making. Yet little is known about the readiness of different types of agricultural advisors to use weather and climate information to help their clients manage risk under increasing climate uncertainty. More than 1700 agricultural advisors in four midwestern states (Nebraska, Indiana, Iowa, and Michigan) completed a web-based survey during the spring of 2012 about their use of weather and climate information, public or private sector employment, and roles as information intermediaries in three advising specializations: agronomic, conservation, and financial. Key findings reveal that advisors who specialize in providing agronomic information are positively inclined toward acting as weather and climate information intermediaries, based on influence and willingness to use climate information in providing many types of operational and tactical advice. Advisors who provide conservation advice appear to be considering weather and climate information when providing tactical and strategic land-use advice, but advisors who provide financial advice seem less inclined to act as climate information intermediaries. These findings highlight opportunities to increase the capacity of different types of advisors to enable them to be effective weather and climate information intermediaries.
Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era
Authors: Graf Solomon A. , Gopal Ajay K. 
Published: November 2014

Abstract
Classical Hodgkin lymphoma (HL) relapses after or is refractory to upfront multiagent chemotherapy in 20%–30% of patients. Effective salvage therapy for relapsed or refractory HL is limited, and advancements are needed. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated significant activity and manageable toxicities in advanced HL. Currently approved as a monotherapy for patients with HL that is relapsed or refractory to multiple lines of chemotherapy or autologous stem cell transplantation, BV is now being evaluated earlier in the course of disease and in combination with other therapies. This review discusses the successful translation of BV from its conception to the clinical setting and highlights ongoing trials that may ultimately expand its role in relapsed or refractory HL and improve outcomes for patients.
Iron clad: iron homeostasis and the diagnosis of hereditary iron overload
Authors: Heeney Matthew M. 
Published: November 2014

Abstract
Iron is an ubiquitous metal of vital importance to the normal physiologic processes of many organisms. Over the last 2 decades, the discovery of mutations in genes leading to hereditary disorders of iron overload, iron deficiency, and iron maldistribution have accelerated our understanding of human iron homeostasis. This chapter provides an updated overview of the human iron cycle, regulation of iron homeostasis, and how perturbations in these homeostatic mechanisms lead to iron overload disease and provides strategies for the diagnosis of hereditary iron overload.
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
Authors: Richardson Paul G. , Laubach Jacob P. , Munshi Nikhil C. , Anderson Kenneth C. 
Published: November 2014

Abstract
For the last 20 years, high-dose therapy with autologous stem cell transplantation (ASCT) for multiple myeloma has been considered a standard frontline treatment for younger patients with adequate organ function. With the introduction of novel agents, specifically thalidomide, bortezomib, and lenalidomide, the role of ASCT has changed in several ways. First, novel agents have been incorporated successfully as induction regimens, increasing the response rate before ASCT, and are now being used as part of both consolidation and maintenance with the goal of extending progression-free and overall survival. These approaches have shown considerable promise with significant improvements in outcome. Furthermore, the efficacy of novel therapeutics has also led to the investigation of these agents upfront without the immediate application of ASCT, and compelling preliminary results have been reported. Next-generation novel agents and the use of monoclonal antibodies have raised the possibility of not only successful salvage strategies to facilitate delayed transplantation for younger patients, but also the prospect of an nontransplantation approach achieving the same outcome. Moreover, this could be achieved without incurring acute toxicity or long-term complications that are inherent to high-dose alkylation, and melphalan exposure in particular. At present, the role of ASCT has therefore become an area of debate: should it be used upfront in all eligible patients, or should it be used as a salvage treatment at the time of progression for patients achieving a high quality of response with initial therapy? There is a clear need to derive a consensus that is useful for clinicians considering both protocol-directed and non-protocol-directed options for their patients. Participation in ongoing prospective randomized trials is considered vital. While preliminary randomized data from studies in Europe favor early ASCT with novel agents, differences in both agents and the combinations used, as well as limited information on overall survival and benefit for specific patient subsets, suggest that one size does not fit all. Specifically, the optimal approach to treatment of younger patients eligible for ASCT remains a key area for further research. A rigid approach to its use outside of a clinical study is difficult to justify and participation in prospective studies should be a priority.
Prevention and treatment of venous thromboembolism in patients with cancer
Authors: Lee Agnes Y.Y. 
Published: November 2014

Abstract
Robust evidence remains scarce in guiding best practice in the prevention and treatment of venous thromboembolism in patients living with cancer. Recommendations from major consensus guidelines are largely based on extrapolated data from trials performed mostly in noncancer patients, observational studies and registries, studies using surrogate outcomes, and underpowered randomized controlled trials. Nonetheless, a personalized approach based on individual risk assessment is uniformly recommended for inpatient and outpatient thromboprophylaxis and there is consensus that anticoagulant prophylaxis is warranted in selected patients with a high risk of thrombosis. Prediction tools for estimating the risk of thrombosis in the hospital setting have not been validated, but the use of prophylaxis in the ambulatory setting in those with a high Khorana score is under active investigation. Symptomatic and incidental thrombosis should be treated with anticoagulant therapy, but little is known about the optimal duration. Pharmacologic options for prophylaxis and treatment are still restricted to unfractionated heparin, low molecular weight heparin, and vitamin K antagonists because there is currently insufficient evidence to support the use of target-specific, non-vitamin K-antagonist oral anticoagulants. Although these agents offer practical advantages over traditional anticoagulants, potential drug interaction with chemotherapeutic agents, gastrointestinal problems, hepatic and renal impairment, and the lack of rapid reversal agents are important limitations that may reduce the efficacy and safety of these drugs in patients with active cancer. Clinicians and patients are encouraged to participate in clinical trials to advance the care of patients with cancer-associated thrombosis.
Management of incidental splanchnic vein thrombosis in cancer patients
Authors: Kreuziger Lisa Baumann , Ageno Walter , Lee Agnes 
Published: November 2014

Abstract
A 75-year-old male with metastatic pancreatic cancer is undergoing chemotherapy with gemcitabine. A portal vein thrombosis was incidentally found on surveillance CT scan. He does not report any new abdominal pain or ascites. Should anticoagulation be used to treat asymptomatic portal vein thrombosis?
RBCs as targets of infection
Authors: McCullough Jeffrey 
Published: November 2014

AbstractRBCs can be targets of infection directly or indirectly. When the microorganism enters the RBC directly, RBC damage becomes a fundamental aspect of the disease process. Malaria is the best example of an organism that directly targets the RBC, but others are Babesia and Bartonella. RBCs can also be indirect targets of infectious agents. This can occur when molecules are bound to the surface of the RBC, leading to immunologic clearance; when microorganism-produced toxins damage the RBC membrane, leading to hemolysis; when previous crypt-antigens are exposed, leading to accelerated removal; when microorganism-produced toxins alter RBC antigens to a different phenotype, or when microorganism suppression of erythropoiesis occurs due to specific binding to RBC precursors.
Reproductive issues in sickle cell disease
Authors: Smith-Whitley Kim 
Published: November 2014

Abstract
As medical advances improve survival, reduce disease-related morbidity, and improve quality of life, reproductive issues will take higher priority in the sickle cell disease (SCD) community. A wide variety of topics are addressed in this chapter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD. Etiologies of impaired male fertility are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complications of medical therapies. Much less is known about the prevalence and etiology of infertility in women with SCD. Other reproductive issues in women included in this review are pain and the menstrual cycle, contraception, and preconception counseling. Finally, long-term therapies for SCD and their impact on fertility are presented. Transfusional iron overload and gonadal failure are addressed, followed by options for fertility preservation after stem cell transplantation. Focus is placed on hydroxyurea therapy given its benefits and increasing use in SCD. The impact of this agent on spermatogenesis, azoospermia, and the developing fetus is discussed.
Does hydroxyurea prevent pulmonary complications of sickle cell disease?
Authors: Buckner Tyler W. , Ataga Kenneth I. 
Published: November 2014

AbstractA 27-year-old man with sickle cell disease (HbSS) presents to the sickle cell clinic for follow-up after a screening echocardiogram revealed an increased tricuspid regurgitant velocity of 2.7 m/s. He has a history of 2 painful crises per year and has been hospitalized 3 times over the past 10 years for management of painful crises. He had one episode of acute chest syndrome at age 15 that was treated with an RBC exchange transfusion, supplemental oxygen, and intravenous antibiotics; he did not require mechanical ventilation. He has not had additional episodes of acute chest syndrome and does not have a history of stroke, retinopathy, or leg ulcers. The patient has never been treated with hydroxyurea. He wants to know whether hydroxyurea will prevent future pulmonary complications related to sickle cell disease.
Thrombotic microangiopathy and indications for therapeutic plasma exchange
Authors: Adamski Jill 
Published: November 2014

Abstract
Thrombotic microangiopathy (TMA) is a clinicopathological condition associated with a wide variety of medical conditions. TMA is classically characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombi that cause end-organ damage. The most prominent diagnoses associated with TMA are thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Although TTP and HUS can have similar clinical and laboratory features and are often lumped together as a combined entity referred to as “TTP/HUS,” the pathologic processes causing TMA and optimal therapies for these conditions are different. Empiric use of therapeutic plasma exchange (TPE) in the setting of TMA is common. The high risk of morbidity and mortality associated with some causes of TMA justify rapid institution of this relatively low-risk procedure. However, many causes of TMA do not respond to TPE and prolonged courses of exchange in the absence of an underlying diagnosis may cause a detrimental delay in appropriate medical therapy. The American Society of Apheresis has published guidelines for the use of TPE for several distinct conditions associated with TMA. This list is not comprehensive and the use of TPE for other causes of TMA may be considered if the mechanism of the underlying disease process provides a clear rationale for this intervention.
Smoothing the crescent curve: sickle cell disease
Authors: Talano Julie-An , Cairo Mitchell S. 
Published: November 2014

AbstractSickle cell disease (SCD) is an inherited disorder secondary to a point mutation at the sixth position of the beta chain of human hemoglobin that results in the replacement of valine for glutamic acid. This recessive genetic abnormality precipitates the polymerization of the deoxygenated form of hemoglobin S that induces a major distortion of red blood cells (sickle red blood cells), which decreases sickle red blood cell deformability, leading to chronic hemolysis and vasoocclusion. These processes can result in severe complications, including chronic pain, end organ dysfunction, stroke, and early mortality. The only proven curative therapy for patients with SCD is myeloablative conditioning and allogeneic stem cell transplantation from HLA-matched sibling donors. In this review, we discuss the most recent advances in allogeneic stem cell transplantation in SCD, including more novel approaches such as reduced toxicity conditioning and the use of alternative allogeneic donors (matched unrelated donors, umbilical cord blood transplantation, haploidentical donors) and autologous gene correction stem cell strategies. Prospects are bright for new stem cell approaches for patients with SCD that will enable curative stem and genetic correction therapies for a greater number of patients suffering from this chronic and debilitating condition.
Eliminating SCID row: new approaches to SCID
Authors: Kohn Donald B. 
Published: November 2014

Abstract
Treatments for patients with SCID by hematopoietic stem cell transplantation (HSCT) have changed this otherwise lethal primary immune deficiency disorder into one with an increasingly good prognosis. SCID has been the paradigm disorder supporting many key advances in the field of HSCT, with first-in-human successes with matched sibling, haploidentical, and matched unrelated donor allogeneic transplantations. Nevertheless, the optimal approaches for HSCT are still being defined, including determining the optimal stem cell sources, the use and types of pretransplantation conditioning, and applications for SCID subtypes associated with radiosensitivity, for patients with active viral infections and for neonates. Alternatively, autologous transplantation after ex vivo gene correction (gene therapy) has been applied successfully to the treatment of adenosine deaminase–deficient SCID and X-linked SCID by vector-mediated gene addition. Gene therapy holds the prospect of avoiding risks of GVHD and would allow each patient to be their own donor. New approaches to gene therapy by gene correction in autologous HSCs using site-specific endonuclease-mediated homology-driven gene repair are under development. With newborn screening becoming more widely adopted to detect SCID patients before they develop complications, the prognosis for SCID is expected to improve further. This chapter reviews recent advances and ongoing controversies in allogeneic and autologous HSCT for SCID.
Optimal disease surveillance strategies in non-Hodgkin lymphoma
Authors: Cohen Jonathon B. , Flowers Christopher R. 
Published: November 2014

AbstractGiven the paucity of randomized controlled trial data, defining the ideal strategy for surveillance imaging in patients with non-Hodgkin lymphoma (NHL) has become increasingly challenging. The routine use of frequent surveillance scans has been a common component of patient care. Emerging data from prospective and retrospective observational studies and modeling approaches have highlighted the performance characteristics of imaging modalities and the challenges with this form of secondary screening. The majority of patients with relapsed lymphoma have clinical signs or symptoms that prompt further evaluation, and only a small proportion of patients experience relapse detected on a routine scan while being otherwise asymptomatic. Surveillance imaging is costly, may expose patients to minimal risks of mortality due to radiation-related secondary malignancies, and can lead to false-positive findings, leading to unnecessary biopsies. In addition, no prospective study has demonstrated a significant improvement in overall survival for those patients whose disease is discovered on a routine scan versus those who present with clinical symptoms. In this chapter, we examine the baseline risks of relapse for various NHL subtypes that provide the context for surveillance, review the data on imaging modalities, and establish a framework for discussing optimal surveillance strategies with individual patients. Patients should be counseled on the risks and benefits of routine surveillance imaging and decisions regarding surveillance should be made on an individual basis using patient-specific risk factors, response to induction therapy, and patient preferences with a bias toward using surveillance imaging in the 2 years after treatment only in those NHL patients with the greatest likelihood of benefit.